Pulmonary rehabilitation to improve physical capacity, dyspnea, and quality of life following pulmonary embolism (the PeRehab study): study protocol for a two-center randomized controlled trial.

Dyspnea Exercise capacity Pulmonary embolism Quality of life Randomized controlled trial Rrehabilitation

Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
06 Jan 2021
Historique:
received: 30 04 2020
accepted: 30 11 2020
entrez: 7 1 2021
pubmed: 8 1 2021
medline: 22 6 2021
Statut: epublish

Résumé

Recently, a large group of patients with persistent dyspnea, poor physical capacity, and reduced health-related quality of life (HRQoL) following pulmonary embolism (PE) has been identified and clustered under the name "post pulmonary embolism syndrome" (PPS). These patients seem good candidates for pulmonary rehabilitation. The aim of the study is to explore whether a pulmonary rehabilitation program can improve physical capacity, dyspnea, and HRQoL in PPS patients. A two-center randomized controlled trial (RCT) is being performed at Østfold Hospital and Akershus University Hospital in Norway. Patients with PPS are 1:1 randomized into an intervention or a control group. The intervention consists of a supervised, outpatient rehabilitation program twice weekly (1 h) for 8 weeks provided by experienced physiotherapists. The intervention involves individually adapted exercises based on existing pulmonary rehabilitation programs (relaxation, interval, and resistance training), and an educational session including topics such as normal anatomy and physiology of the respiratory and circulatory system, information on PE/PPS, breathing strategies, and benefits of exercise/physical activity. Patients randomized to the control group receive usual care without specific instructions to exercise. Participants in the intervention and control groups will be compared based on assessments conducted at baseline, 12 weeks, and 36 weeks after inclusion using the incremental shuttle walk test (primary outcome) and endurance shuttle walk test (exercise capacity), Sensewear activity monitor (daily physical activity), the modified Medical Research Council scale, the Shortness of Breath Questionnaire (dyspnea), and EQ-5D-5L and the Pulmonary Embolism Quality of Life Questionnaire (HRQoL). Recruitment of 190 patients is currently ongoing. Results from this study may provide a currently untreated group of PPS patients with an effective treatment resulting in reduced symptoms of dyspnea, improved exercise capacity, and better HRQoL following PE. Clinical Trials NCT03405480 . Registered prospectively on September 2017. Protocol version 1 (from original protocol September 2017). The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 1).

Sections du résumé

BACKGROUND BACKGROUND
Recently, a large group of patients with persistent dyspnea, poor physical capacity, and reduced health-related quality of life (HRQoL) following pulmonary embolism (PE) has been identified and clustered under the name "post pulmonary embolism syndrome" (PPS). These patients seem good candidates for pulmonary rehabilitation. The aim of the study is to explore whether a pulmonary rehabilitation program can improve physical capacity, dyspnea, and HRQoL in PPS patients.
METHODS METHODS
A two-center randomized controlled trial (RCT) is being performed at Østfold Hospital and Akershus University Hospital in Norway. Patients with PPS are 1:1 randomized into an intervention or a control group. The intervention consists of a supervised, outpatient rehabilitation program twice weekly (1 h) for 8 weeks provided by experienced physiotherapists. The intervention involves individually adapted exercises based on existing pulmonary rehabilitation programs (relaxation, interval, and resistance training), and an educational session including topics such as normal anatomy and physiology of the respiratory and circulatory system, information on PE/PPS, breathing strategies, and benefits of exercise/physical activity. Patients randomized to the control group receive usual care without specific instructions to exercise. Participants in the intervention and control groups will be compared based on assessments conducted at baseline, 12 weeks, and 36 weeks after inclusion using the incremental shuttle walk test (primary outcome) and endurance shuttle walk test (exercise capacity), Sensewear activity monitor (daily physical activity), the modified Medical Research Council scale, the Shortness of Breath Questionnaire (dyspnea), and EQ-5D-5L and the Pulmonary Embolism Quality of Life Questionnaire (HRQoL). Recruitment of 190 patients is currently ongoing.
DISCUSSION CONCLUSIONS
Results from this study may provide a currently untreated group of PPS patients with an effective treatment resulting in reduced symptoms of dyspnea, improved exercise capacity, and better HRQoL following PE.
TRIAL REGISTRATION BACKGROUND
Clinical Trials NCT03405480 . Registered prospectively on September 2017. Protocol version 1 (from original protocol September 2017). The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 1).

Identifiants

pubmed: 33407792
doi: 10.1186/s13063-020-04940-9
pii: 10.1186/s13063-020-04940-9
pmc: PMC7789311
doi:

Banques de données

ClinicalTrials.gov
['NCT03405480']

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

22

Subventions

Organisme : Sykehuset Østfold
ID : 15/00601-56

Références

Chest. 2014 Jun;145(6):1357-1369
pubmed: 24384555
Vasc Health Risk Manag. 2015 Jul 13;11:397-401
pubmed: 26203256
Chron Respir Dis. 2016 Aug;13(3):229-39
pubmed: 27072018
JAMA Netw Open. 2020 Feb 5;3(2):e200064
pubmed: 32108888
Interact J Med Res. 2014 Oct 27;3(4):e14
pubmed: 25347989
Chest. 2017 May;151(5):1058-1068
pubmed: 27932051
Am J Respir Crit Care Med. 2013 Oct 15;188(8):e13-64
pubmed: 24127811
Blood Rev. 2014 Nov;28(6):221-6
pubmed: 25168205
Trials. 2017 May 30;18(1):245
pubmed: 28558825
Physiol Rep. 2013 Nov;1(6):e00150
pubmed: 24400152
J Thromb Haemost. 2015 Jul;13(7):1238-44
pubmed: 25912176
Thorax. 2008 Sep;63(9):775-7
pubmed: 18390634
Am J Respir Crit Care Med. 2010 Mar 1;181(5):501-6
pubmed: 19965808
Hamostaseologie. 2018 Feb;38(1):22-32
pubmed: 29536477
Chest. 2016 Feb;149(2):315-352
pubmed: 26867832
Nat Rev Dis Primers. 2018 May 17;4:18028
pubmed: 29770793
Chron Respir Dis. 2006;3(1):3-9
pubmed: 16509172
BMJ Open. 2016 Nov 3;6(11):e013086
pubmed: 27810979
Eur J Intern Med. 2008 Dec;19(8):625-9
pubmed: 19046730
Eur Heart J. 2020 Jan 21;41(4):543-603
pubmed: 31504429
J Am Med Dir Assoc. 2017 Jan;18(1):53-58
pubmed: 27624705
Thorax. 1999 Mar;54(3):213-22
pubmed: 10325896
J Thromb Haemost. 2018 Dec;16(12):2454-2461
pubmed: 30240543
Eur J Prev Cardiol. 2015 Aug;22(8):972-8
pubmed: 24958737
J Thromb Haemost. 2010 Mar;8(3):523-32
pubmed: 20025645
Thromb Res. 2018 Apr;164:170-176
pubmed: 28760416
Med Sci Sports Exerc. 1982;14(5):377-81
pubmed: 7154893
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777

Auteurs

Stacey Haukeland-Parker (S)

Department of Physical Medicine and Rehabilitation, Østfold Hospital Trust, PB 300, 1714, Grålum, Norway. stacey.haukeland.parker@so-hf.no.
Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medicine, University of Oslo, Oslo University Hospital, Oslo, Norway. stacey.haukeland.parker@so-hf.no.

Øyvind Jervan (Ø)

Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medicine, University of Oslo, Oslo University Hospital, Oslo, Norway.
Department of Internal Medicine, Østfold Hospital Trust (number 3), Grålum, Norway.

Hege Hølmo Johannessen (HH)

Department of Physical Medicine and Rehabilitation, Østfold Hospital Trust, PB 300, 1714, Grålum, Norway.
Department of Health and Welfare, Østfold University College, Fredrikstad, Norway.

Jostein Gleditsch (J)

Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medicine, University of Oslo, Oslo University Hospital, Oslo, Norway.
Department of Radiology, Østfold Hospital Trust, Grålum, Norway.

Knut Stavem (K)

Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medicine, University of Oslo, Oslo University Hospital, Oslo, Norway.
Department of Pulmonary Medicine, Medical Division, Akershus University Hospital, Lørenskog, Norway.
Health Services Research Unit, Akershus University Hospital, Lørenskog, Norway.

Kjetil Steine (K)

Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medicine, University of Oslo, Oslo University Hospital, Oslo, Norway.
Department of Cardiology, Medical Division, Akershus University Hospital, Lørenskog, Norway.

Martijn A Spruit (MA)

Department of Research and Development, CIRO+, Horn, The Netherlands.
Department of Respiratory Medicine, Maastricht University Medical Center (MUMC+), and NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands.
REVAL Rehabilitation Research Center, BIOMED Biomedical Research Institute, Faculty of Rehabilitation Sciences, Hasselt University, Diepenbeek, Belgium.

René Holst (R)

Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medicine, University of Oslo, Oslo University Hospital, Oslo, Norway.
Department of Internal Medicine, Østfold Hospital Trust (number 3), Grålum, Norway.

Mazdak Tavoly (M)

Department of Internal Medicine, Østfold Hospital Trust (number 3), Grålum, Norway.
Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.

Frederikus A Klok (FA)

Department of Medicine - Thrombosis and Haemostasis, Leiden University Medical Center, Leiden, The Netherlands.

Waleed Ghanima (W)

Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medicine, University of Oslo, Oslo University Hospital, Oslo, Norway.
Departments of Research, Emergency Medicine and Hematooncology, Østfold Hospital Trust, Grålum, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH